• Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

The efficacy of 48 weeks treatment with besifovir dipivoxil maleate (BSV) for chronic hepatitis B virus (HBV) infection is comparable to that of tenofovir disoproxil fumarate (TDF), with durable effects for 96 weeks, researchers report in the August issue of Clinical Gastroenterology and Hepatology. BSV has a better safety profile

Read more
  • How Does Gastroparesis Vary Among Different People?

How Does Gastroparesis Vary Among Different People?

Gastroparesis causes, symptoms, and treatments vary among patients of different races, ethnicities, and sexes, researchers report in the July issue of Clinical Gastroenterology and Hepatology. The prevalence of some gastrointestinal (GI) disorders varies with race and ethnicity. For example, dyspepsia and irritable bowel syndrome are reported less frequently by African Americans.

Read more

Is an Endoscopic Transluminal Approach Better Than Surgery for Patients With Necrotizing Pancreatitis?

An endoscopic transluminal approach for treatment of infected necrotizing pancreatitis, compared with minimally invasive surgery, significantly reduced major complications, lowered costs, and increased quality of life, according to a randomized trial published in the March issue of Gastroenterology. Acute pancreatitis is the third most common gastrointestinal disorder in the United

Read more
  • Can an Antibody Against IL13 Be Used to Treat Eosinophilic Esophagitis?

Can an Antibody Against IL13 Be Used to Treat Eosinophilic Esophagitis?

A monoclonal antibody against IL13 reduced histologic and endoscopic features of eosinophilic esophagitis (EoE) in a placebo-controlled phase 2 trial, researchers report in the February issue of Gastroenterology. The antibody, called RPC4046, was well tolerated. EoE is a chronic, immune-mediated disease of the esophagus characterized by eosinophil-mediated mucosal inflammation and

Read more
  • What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

More than 95% of patients with hepatitis C virus–associated cryoglobulinemia vasculitis (HCV-CryoVas) have a full or partial response of symptoms to treatment with direct-acting antiviral (DAA) agents, researchers report in a long-term follow-up study in the February issue of Clinical Gastroenterology and Hepatology. Fewer than 5% of patients stopped therapy

Read more
  • What is the Best Treatment Option for Fistulizing Crohn’s Disease?

What is the Best Treatment Option for Fistulizing Crohn’s Disease?

Tumor necrosis factor (TNF) antagonists are effective for induction and maintenance of perianal fistula response and remission in patients with Crohn’s disease (CD), a systematic review and meta-analysis shows in the December issue of Clinical Gastoenterology and Hepatology. However, there are few data on the effects on internal fistulae, and further studies

Read more
  • Does Colony Stimulating Factor Increase Survival of Patients with Alcoholic Hepatitis?

Does Colony Stimulating Factor Increase Survival of Patients with Alcoholic Hepatitis?

In a pilot study from the October issue of Clinical Gastroenterology and Hepatology, colony stimulating factor 3 (CSF3, also called GCSF) improved liver function and increased survival times in patients with severe alcohol-associated hepatitis (AH), compared with standard therapy. Addition of N-acetyl cysteine (NAC) to GCSF did not improve patient outcomes. Patients

Read more
  • Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Little is known about the efficacy and safety of combination targeted therapy for inflammatory bowel diseases (IBD), despite their use in treatment of other immune-mediated disorders. In a review article in the September issue of Clinical Gastroenterology and Hepatology, Robert P. Hirten et al discuss findings from studies of biologic

Read more
  • What are the Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis?

What are the Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis?

Vitamin K antagonists (VKAs) increase risk of minor bleeding in patients with cirrhosis given anticoagulants for portal vein thrombosis (PVT), compared to patients without cirrhosis given VKAs, researchers report in the July issue of Clinical Gastroenterology and Hepatology. However, this risk is offset by the ability of VKA to increase portal

Read more
  • What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

Despite advances in methods of clinical trials for ulcerative colitis (UC), there is still a large amount of variation in endpoints, even in definitions of response and remission, reseachers found in a systematic review published in the May issue of Clinical Gastroenterology and Hepatology. The authors conclude that we need a

Read more